RFA-AI-16-065: Asthma and Allergic Diseases Cooperative Research Centers (U19)
LOI: March 3, 2017
Internal Deadline: Contact the Office of Research if interested.
External Deadline: April 3, 2017, 5pm PDT
Type: Cooperative Agreement
Estimated Number of Awards: 4 – 5
Anticipated Amount: $900,000 in direct cost per year
Cost Sharing: This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
Submission Process: PIs must submit their application as a Limited Submission through the Office of Research Application Portal: https://app.wizehive.com/webform/USCgrants
Materials to submit:
- Single Page Proposal Summary (0.5” margins; single-spaced; font type: Arial, Helvetica, or Georgia typeface; font size: 11 pt.).
- CV – (5 pages maximum)
Who May Serve as PI: Standard NIH requirements.
The program will support centers that integrate clinical and basic research to conduct studies on the mechanisms underlying the onset and progression of diseases of interest including asthma, rhinitis (allergic and non-allergic), chronic rhinosinusitis, atopic dermatitis, food allergy, and drug allergy. The overarching goal of the program is to improve the understanding of the pathogenesis of these conditions and to provide a rational foundation for new, effective treatments and prevention strategies.
NIAID programmatic priorities for this FOA are:
- The role of innate and adaptive immune functions in the development and pathogenesis of asthma and allergic diseases with focus on severe asthma, chronic rhinosinusitis, atopic dermatitis and drug allergy;
- The impact of the microbiome and pollution on immune responses as they pertain to the development, prevention and management of asthma, allergic rhinitis, food allergy and atopic dermatitis;
- The interaction between infections and atopy and the role of immune responses to infections in the development and exacerbations of asthma, allergic rhinitis, chronic rhinosinusitis and atopic dermatitis;
- Induction of and understanding of the mechanisms of desensitization and sustained tolerance for the treatment and prevention of asthma, allergic rhinitis, food allergy and drug allergy;
- Genetic variations and epigenetic alterations affecting host immune responses to aeroallergens, food allergens and drug allergens;
- Clinical, immunologic and physiologic phenotyping and endotyping of drug allergy, atopic dermatitis, chronic rhinosinusitis and non-allergic rhinitis syndromes.
Visit our Institutionally Limited Submission webpage for updates and other announcements.